个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共9条记录   XOMA-052 Humanized Anti-IL-1 beta Monoclonal Antibody Treatment of Diabetes Treatment of Rheumatoid Arthritis Treatment of Cardiovascular Disorders [作者：Krakowski, ML; Horwitz, MS,期刊：Drugs of the Future, 页码：553-556 , 文章类型： Article，,卷期：2010年35-7] XOMA-052 is a humanized monoclonal antibody specific for human interleukin-1 (IL-1 beta) currently in phase II clinical trials in both Europe and the U.S. for the treatment of type 2 diabetes. Type 2 diabetes is an adult... CLINICAL ASPECTS OF MODULATION OF GLUTAMATERGIC MECHANISMS IN THE TREATMENT OF SCHIZOPHRENIA [作者：Kinon, BJ,期刊：Drugs of the Future, 页码：557-566 , 文章类型： Review，,卷期：2010年35-7] Current treatments for schizophrenia all target the dopamine 02 receptor but may have limited effectiveness, particularly in treating the negative and persistent positive symptoms, as well as the cognitive impairment ass... FACING DYSKINESIA IN PARKINSON'S DISEASE: NONDOPAMINERGIC APPROACHES [作者：Salamone, JD,期刊：Drugs of the Future, 页码：567-573 , 文章类型： Review，,卷期：2010年35-7] L-DOPA has been the gold standard for the treatment of Parkinson's disease for the last 5 decades. Nevertheless, problems with long-term use, such as motor fluctuations and dyskinesias, have led investigators to search f... OSTEOGENESIS IMPERFECTA: CURRENT AND FUTURE TREATMENTS [作者：Shapiro, JR; Kantipuly, A; Rowe, D,期刊：Drugs of the Future, 页码：575-584 , 文章类型： Article，,卷期：2010年35-7] Osteo genesis imperfecta (OI) is a heritable disease of bone due to mutations involving type I collagen synthesis. Current concerns in both children and adults involve the effectiveness of intravenous and orally administ... THERAPEUTIC TARGETS FOR GLAUCOMA [作者：Sorbera, LA; Aravamudan, J; Dulsat, C; Rosa, E,期刊：Drugs of the Future, 页码：585-592 , 文章类型： Article，,卷期：2010年35-7] Glaucoma is a group of progressive optic neuropathies that involves the death of retinal ganglion cells, the consequent deformation of the optic nerve head and a progressive reduction in the visual field. The disease can... A REPORT FROM THE 59TH ANNUAL SCIENTIFIC SESSION OF THE AMERICAN COLLEGE OF CARDIOLOGY [作者：Rabasseda, X,期刊：Drugs of the Future, 页码：593-604 , 文章类型： Article，,卷期：2010年35-7] This meeting report summarizes the most important data presented at the 59th Annual Scientific Session of the American College of Cardiology (ACC.10 & 12 Summit), which was held at the Georgia World Congress Center in At... DUTOGLIPTIN TARTRATE Dipeptidyl Peptidase 4 Inhibitor Treatment of Diabetes [作者：Haddley, K,期刊：Drugs of the Future, 页码：529-535 , 文章类型： Article，,卷期：2010年35-7] Following consumption of a meal, plasma glucose levels are managed by insulin and glucagon release. The postprandial release of insulin and glucagon is regulated by the incretin hormones glucagon-like peptide 7 (GLP-1) a... LANINAMIVIR OCTANOATE Neuraminidase Inhibitor Treatment of Influenza [作者：Reviriego, C,期刊：Drugs of the Future, 页码：537-545 , 文章类型： Article，,卷期：2010年35-7] Influenza is an extremely contagious disease caused by infection with influenza A and B viruses. The available treatments for influenza include two types of drugs: M2 ion channel inhibitors and neuraminidase (NA) inhibit... PALIFOSFAMIDE TROMETHAMINE DNA-Alkylating Agent Oncolytic [作者：Rasila, KK; Verschraegen, CF,期刊：Drugs of the Future, 页码：547-552 , 文章类型： Article，,卷期：2010年35-7] Palifosfamide is a novel, bifunctional DNA cross-linker that is the stabilized active metabolite of ifosfamide. Isophosphoramide mustard, the active metabolite of ifosfamide, is not suitable for administration because of...